Canada's Generics Export Program Falters Amid Litigation Fears

Law360, New York (November 26, 2004, 12:00 AM EST) -- Canadian generic drug makers are opting out of the country’s trailblazing efforts to supply developing countries with patented drugs, blaming excessive safeguards for patent holders under the new law, according to a published report.

Drug makers are choosing not to participate in the government's generic export scheme due to the lack of financial incentives, Jeff Connell of the Canadian Generic Pharmaceutical Association (CGPA) told the Inter Press Service.

In May, Canada passed the Jean Chrétien Pledge to Africa Act, named after the country’s former Prime Minister,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.